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INTRODUCTION 
Recently there is an increase in concerns about ambulatory surgery 
among surgeons as it facilitates early hospital discharge, less health care 
related and improving post-operative quality of life. However this has 
cause new challenges to the attending anesthesiologists as anesthesia 
management for ambulatory surgery needs careful titration of anesthetic 
agents targeting at early post-operative recovery, stable hemodynamics in 
intra operative and post-operative period and adequate pain relief without 
any sedation in post-operative period.  
In common with all other types of pain, acute postoperative pain is 
an extraordinarily complex sensation which may be described as an 
interpretation of these signals by higher centers involving memory 
experiences of painful situation, and an affective component which 
generally comprises anxiety and /or depression.  
Uncontrolled post-operative pain has an adverse sequel of delayed 
resumption of normal pulmonary function, restriction of mobility (thus 
contributing to thromboembolic complications), nausea, vomiting and 
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cardiac work load was increased and myocardial oxygen consumption 
also increased due to catecholamine release induced by the stress 
response.  
Post-operative pain control is an essential component of Anesthesia 
management. Adequate pain control is one of the crucial factors in 
ambulatory surgical plan. Management Plan should be aimed at providing 
adequate pain relief and at the same time minimizing side effects like 
sedation. So that the patient can be safely discharged from surgical 
facility without any major influence on the patient’s ability to resume 
their normal activities of daily living. Control of acute post-operative pain 
and the timing, and duration (e.g., Pre-emptive Analgesia), is important  
in facilitating short and long-term patient convalescence.  
For many years, Opioid based perioperative Analgesia 
Management was being used. Although potent analgesics opiods are 
associated with multiple perioperative side effects including respiratory 
depression, sedation and drowsiness, urinary retention, post-operative 
nausea and vomiting, pruritus and decrease in bowel movements leading 
to Ileus and constipation. These side effects may lead to prolonged post-
operative stay, delay hospital discharge and increase in hospitalization 
costs.  
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In addition, the use of conventional method of administration of 
intra-muscular opioids in standard prescribed doses, may be too large 
(causing side effects), or too small (causing inadequate analgesia). 
Therefore, Anesthesiologist are increasingly concerned towards non-
conventional techniques as adjuvant for managing post-operative pain to 
reduce the adverse effects of opioid based Analgesic drugs.  
From the non-conventional methods, the infiltration of long-acting 
local Anaesthetics as an adjuvant for regional or local anaesthetic 
techniques, improve postoperative pain management, furthermore, when 
administrated before surgery, these simple techniques can also decrease 
anaesthetic and requirement of analgesia during surgery as well as reduce 
the need for opioid containing analgesic postoperatively.  
Inspite of several advantages of laparoscopic procedures over 
laparotomy, it does not take away the disadvantage like the post-operative 
pain which results in an unpleasant experience for the patient and thereby 
delay the discharge. Pain usually occurs on the first day following surgery 
and it may be a visceral, parietal or shoulder pain.  
By evaluating the patho-physiology of pain it is shown that we can 
prevent or reduce pain by blocking the nociceptors before their 
stimulation by use of local anaesthetics.   
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Post-operative right upper abdominal pain and shoulder is a diffuse 
abdominal which was experienced on the day of surgery. The cause of 
this pain is thought to be related to abdominal muscle distension during 
laparoscopic procedure, irritative effects of residual Carbon-di-oxide in 
the abdominal cavity and prolonged elevation of diaphragm by 
pneumoperitoneum. 
BACKGROUND 
Post-operative pain after laproscopic cholecystectomy procedures 
are being rated from mild to severe in the literature. Post operative pain 
Most of the patients suffer from miled to severe pain after laparoscopic 
cholecystectomy. Different modalities for adequate control of pain 
management in these scenario are described including opioids, NSAIDs, 
local anesthetic infiltration of port site and local anesthesia infusion 
through epidural route, but none of them are proven to be consistently 
satisfactory.   
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AIMS AND OBJECTIVES 
To study the impact of intravenous Lignocaine on intra-operative 
Haemodynamics, recovery characteristics, post-op pain scores, post-op 
analgesic requirement and return of bowel function in patients 
undergoing  Laproscopic  Cholecystectomy. 
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LAPAROSCOPY 
Laparoscopy conventionally means visualization of the abdominal 
cavity through an especially designed scope (Endoscope). 
TECHNIQUE OF LAPAROSCOPY 
In laparoscopic surgeries, gas will be insufflated (usually 
carbondioxide) into the abdominal cavity under pressure to separate the 
organs from the abdominal wall. This produces a pneumoperitoneum, 
leading to increase in intra-abdominal pressure. Gas is insufflated in the 
peritoneal cavity at an initial rate of 4-6 liter per minute which gets cut 
off when the intra-abdominal pressure exceeds the pressure limits set by 
the clinician (usually 12-14 mm Hg). After the initial insufflations, the 
pneumoperitoneum and the pressure is maintained by a constant flow of 
200-400 ml per minute of insufflating gas. 
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VENTILATORY AND RESPIRATORY CHANGES DURING 
LAPAROSCOPY WITH CO2  PENUMOPERITONEUM  
EFFECT OF RAISED INTRA-ABDOMINAL PRESSURE 
There is a cephalad displacement of the diaphragam due to the 
increased intra abdominal pressure which causes reducing FRC and 
compliance by as much as 30% to 50%, Peak airway pressure and plateau 
pressures rise by 50% and 80%, respectively, and pulmonary compliance 
is reduced by 47%. This results in an increase in the airway resistance and 
work of breathing. Intrapulmonary shunting common in obese which is 
the cause for Hypoxemia. 
INCREASE IN PARTIAL PRESSURE OF CO2 
There is increase in PaCO2 when carbondioxide is used to create 
pneumoperitoneum. This PaCO2 rises gradually and reaches a Plateau  
20 to 30 min. after the beginning of intra-peritoneal insufflations.  
The increase in PaCO2 values correlates with increase in the intra-
abdominal pressure and ranges between 15% and 30%. In patients 
without respiratory or cardio-vascular co morbid illness, the increase in 
PaCO2 results mainly due to CO2 absorption from pneumoperitoneum. 
This pneumoperitoneum does not significantly modify physiologic dead 
space or shunt and as a result, the gradient between PaCO2 and end-tidal 
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PCO2 does not change. Due to this correlation end-tidal monitoring of 
Carbondioxide adequately reflects PaCO2 values in blood and can be used 
to guide adjustment of ventilation so that hyper-capnia can be avoided.  
In patients with impaired pulmonary ventilation and perfusion matching 
like chronic obstructive pulmonary diseases, the resulting increased 
physiologic dead space and reduced alveolar ventilation leads to 
increased PaCO2 to end-tidal CO2 gradient. This leads to an increase in 
PaCO2 values and adequate hyper-ventilation is required, so that hyper-
capnia can be avoided. In these patients, capnography may not provide 
reliable measurement of PaCO2. It is shown in studies that diffusion of 
Carbondioxide diffusion to the body is more during extra-peritoneal than 
intra-peritoneal insufflations. Also extra-peritoneal Carbondioxide 
insufflations  lead to higher PaCO2 values in the post-operative period. 
CHANGE IN MINUTE VENTILATION 
During laparoscopy with local anesthesia, minute ventilation 
increase by as much as 60% to maintain normo-capnea. If general 
anesthesia is maintained without muscle relaxation, i.e., with spontaneous 
breathing, the compensatory hyper-ventilation may not occur due to of 
anesthetic-induced respiratory depression leading to hyper-capnia.  
If the patients who were maintained on controlled ventilation, it is shown 
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that 15 to 20% increase in minute Ventilation is needed to prevent 
increase in PaCO2. 
RESPIRATORY COMPLICATIONS CAN OCCUR  
DURING LAPAROSCOPY 
The major complication which can occur during Laparoscopy are : 
1. Carbondioxide subcutaneous emphysema  
- due to extra peritoneal insufflations 
2. Pneumothorax, Pneumomediastinum, Pneumopericardium 
3. Endobronchial intubation  
- due to cephalad movement of the diaphragm 
4. Gas Embolism 
5. Aspiration of Gastric contents. 
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HEMODYNAMIC CHANGES DURING  
LAPAROSCOPY WITH CO2 
PNEUMOPERITONEUM 
EFFECTS OF HYPERCAPNIA 
Hypercapnia due to CO2 pneumoperitoneum leads to activation of 
the sympathetic nervous system, that in turn leads to increase in arterial 
blood pressure, increase in heart rate, increase in myocardial contractility, 
and it may even lead to arrhythmias. Increase in Carbondioxide content in 
blood sensitizes the myocardium to circulating catecholamines, and this 
phenomenon is exaggerated particularly when inhalational anesthetic 
agents are used for maintenance of anesthesia. 
EFFECTS OF RAISED INTRA-ABDOMINAL PRESSURE   
Intra-abdominal pressure maintained less than 15mm Hg causes 
increase in venous return to heart, as blood is squeezed out of the 
splanchnic and mesenteric venous system, and leading to an increase in 
cardiac output. 
On the other hand, when intra-abdominal pressure is maintained  
more than 15mm Hg, Cardiac output decreases transiently due to : 
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1. DECREASED VENOUS RETURN 
a. Inferior vena cava obstruction. 
b. Pooling of blood in the legs 
c. Increased venous resistance 
2. MYOCARDIAL DEPRESSANT EFFECT OF 
ANESTHESIA INDUCTION AGENTS 
3. RAISED SYSTEMIC VASCULAR RESISTANCE 
a. Release of neuro-humoral factors 
b. Increased vascular resistance of organs 
The increase in systemic vascular resistance causes an increase in 
arterial pressures. Central venous pressure and pulmonary artery wedge 
pressure are elevated due to increased intra-thoracic pressure and in the 
scenario of pneumoperitoneum these cannot be considered as reliable 
indicators of cardiac filling pressures. Cardiac arrhythmias during 
laparoscopy are due to multiple causes-hypercapnia, peritoneal 
stimulation, reduced venous return, hypo-volemia and venous gas 
embolism. 
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EFFECTS OF PNEUMOPERITONEUM ON  
OTHER ORGAN SYSTEMS 
Renal Effects : There is a decrease in renal blood-flow and 
Glomerular Filtration rate due to the reduction in cardiac output. Renal 
vascular resistance may also increase due to the raised intra-abdominal 
pressure. This can manifest as a reduction in intra-operative urine output. 
Patients with pre-existing renal dysfunction are at risk of further 
deterioration. However, normally these changes are reversible and the 
urine output improves once intra-abdominal pressure comes down at the 
end of surgery. 
Splanchnic and Hepatic Blood-Flow: The effect of 
penumoperitoneum on splanchnic and hepatic blood-flow is unclear. 
Anim al studies suggest that while hypercapnia has a vasodilatory effect, 
this is opposed by the vasoconstricting effect of the raised intra-
abdominal pressure. 
Gastrointestinal Effects: Raised intra-abdominal pressure can 
predispose the patient to regurgitation and aspiration. However, it is 
believed that the changes in the intra-abdominal pressure are transmitted 
to the lower esophageal sphincter, preventing this complication. 
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Neurologic Effects: The combination of factors like hyper-capnia, 
head-low position, and elevated systemic vascular resistance can leads to 
increase in intra-cranial pressure with a resultant decrease in cerebral 
perfusion pressure. This may be exaggerated in patients with 
ventriculoperitoneal shunts which do not have a unidirectional valve. 
Ocular Effects: A slight increase in intraocular pressure has been 
described, though its clinical significance is not clear. 
Neuroendocrine Effects: Increased levels of stress hormones. 
Increase in ADH and aldosterone levels. 
EFFECTS OF POSITION 
Laparoscopic Cholecystectomy is usually carried out in the reverse 
Trendelenberg positon, with the patient’s arms by the side. This position 
helps by displacing the abdominal organs far from the surgical site,  
to facilitate surgical accessibility. 
For laparoscopic procedures depending on site of surgery either 
trendelenburg (for pelvic surgeries) or reverse trendelenburg (for upper 
abdominal surgeries) position is used. The effects of surgical positioning 
are: 
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• Reverse Trendelenburg (Head-up):    Preload is decreased, 
resulting in lowered pressure (MAP). Blood pooling in the lower 
extremities may increase the risk of venous thrombosis and 
pulmonary function is improved. 
• Trendelenburg Position (Head down):   Cardiac output and 
central venous pressure increase. Pulmonary effects include 
impaired diaphragmatic function secondary to the Cephalad 
displacement of abdominal viscera, resulting in decreased 
functional residual capacity, decreased total lung capacity, and 
decreased pulmonary compliance, predisposing the patient to 
developing atelectasis. Cephalad movement of the trachea may 
result in endobronchial intubation. 
Intravenous Lignocaine has been used to suppress cough during 
tracheal intubation, Laryngospasm and cough during extubation. It has  
also been used to suppress airway hyperactivity and mitigate broncho-
constriction after tracheal intubation.  
PHYSIOLOGY OF PRESSURE RESPONSES 
Direct laryngoscopy and tracheal intubation following induction of 
anaesthesia is almost always with hemodynamic changes due to reflex 
sympathetic stimulation. Herein, with have explained briefly, the 
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Physiology and effects of Laryngoscopy and Intubation to understand the 
haemo-dynamic changes.  
SYMPATHETIC NERVOUS SYSTEM 
The sympathetic efferent nerve fibres originate from nerve cells in 
the lateral grey column of the spinal cord between the 1stthoracic and  
2nd lumbar segments. Pre-ganglionic fibres are myelinated. Ganglia 
situated either in the para-vertebral sympathetic trunk or in pre-vertebral 
ganglia, such as the celiac ganglion. The sympathetic part of 
postganglionic fibres are long, non-myelinated sympathetic part of the 
system has a wide spread action on the body as the resulting 
preganglionic fibres synapsing on many postganglionic nerve fibres and 
the suprarenal medulla releasing the sympathetic transmitters epinephrine 
and nor epinephrine. The sympathetic nervous system prepares the body 
for emergency situation and sever muscular activity. There is no 
sympathetic out flow from cervical part of the cord nor from the lower 
lumbar and sacral parts. Those pre-ganglionic fibres which are destined to 
synapse with cell bodies whose fibres are going to run with cervical 
nerves must ascend in the sympathetic trunk and those of lower lumbar 
and sacral nerves must descend in the trunk to lumbar and sacral ganglia. 
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THE CARDIOVASCULAR REFLEXES 
The cardiovascular and hemodynamic responses to airway 
manipulation are caused by firing of proprioceptors located in the  
supraglottic region and tracheal mucosa. These pro-prioceptors are 
actually mechano receptors consisting of small diameter myelinated 
fibers; slow adapting stretch receptors with large diameter myelinated 
fibres and polymodal endings of non-myelinated nerve fibers. These 
receptors are located in close proximity to airway mucosa. Stimulation of 
these receptors lead to afferent impulse to brain stem transmitted through 
glossopharyngeal and vagal nerves and this in turn leads to activation of 
autonomic nervous system including both sympathetic and 
parasympathetic nervous system manifesting as hemodynamic and 
cardiovascular events. The superficial location of the pro-prieoceptors 
and their nerves has the advantage that topical anaesthesia of the airway 
with local anesthetics provides an effective means of blunting 
cardiovascular and hemodynamic responses to airway manipulations. 
In adults and adolescents, the most common result of airway 
manipulation is increase in blood pressure and increase in heart rate. 
These are mediated by the sympathetic chain ganglia and cardio 
accelerator fibers arising from them. This response leads to secretion of  
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noradrenaline from sympathetic nerve terminals and adrenaline from the 
adrenal medulla.  
Following intubation stimulation of cerebral cortical activity is also 
shown to be increased leading to increase in elctro-encephalographic 
activity, increased metabolic rate and increase in cerebral blood-flow 
corresponding to increase in metabolic activity.  
PHARMACOLOGY OF LOCAL ANAESTHETICS STRUCTURE 
ACTIVITY RELATIONSHIP OF LOCAL ANAETHETICS 
Local Anaesthetics contains lipophilic group, a Benzene ring, 
separated from a hydro-philic group, usually a tertiary amine, by an 
intermediate chain which includes an ester or amide linkage.  
Local Anaesthetics are weak bases. At physiological pH they usually 
carry a positive charge at the tertiary amine. On the basis of the nature of 
the intermediate chain local anaestheticsare classified into Amide or Ester 
groups. Local anaesthetics act by penetrating lipoprotein cell membrane 
in the non-ionized state. In order to make them suitable for injection, the 
non-ionized base has to be converted to the ionized state by injecting 
them in an acid solution as the hydrochloric salt so, tertiary amine group 
becomes quaternary and then they become water soluble and suitable for 
injection.  
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STRUCTURAL ACTIVITY RELATIONSHIP  
A) POTENCY 
An increase in the lipid solubility and/or increase in the molecular 
weight increase the potency of local anaesthetic, e.g., adding a butyl 
group to Mepivacaine (less potent local Anaesthetic) converts it into 
Bupivacaine  (more potent local Anaesthetic).  
POTENCY IS AFFECTED BY  
1. Fiber Size: The smaller unmyelinated fibers (e.g. sensor C 
Fibers) are more effectively blocked than the large myelinated 
fibers (motor A Fibers).  
2. pH: Acidic environment decreases the potency.  
3. Nerve Firing Frequency: Access of local Anaesthetic to  
Na channels is enhanced by repeated opening of those channels.  
B) SPEED OF ONSET OF ACTION: AND THIS DEPENDS 
ON:  
1. pKa of the Drug:  When the pKa of local Anaesthetics are closer 
to the physiologic pH the onset of action is enhanced. This is due 
to higher concentration of the non-ionized free base at 
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physiological pH that enhances the drug crossing the nerve cell 
membrane.  
2. Molecular weight: Local anaesthetics with smaller molecular 
weight have more rapid onset of action.  
C) DURATION OF ACTION  
It depends on the aromatic group which affects the plasma protein 
binding. The higher the plasma protein binding the slower the clearance 
and thus the higher the duration of action. Also, higher protein binding 
increase the duration of affection of the local anaesthetic to the  
Na channels and thus prolong the action.  
The myelinated nerves are protected by the myelin sheath which 
acts as an insulator. Outside of nerve membrane a resting potential of  
70mV is maintained when there are no stimulation, and called as resting 
membrane potential. During any stimulation the Resting membrane 
potential rises to about 55mV , the firing threshold, before it jumps upto 
+20mV to form an action potential which constitutes a change of about 
90 mV. This is caused by influx of sodium ions and efflux of potassium 
ions through ion channels located in the cell wall. The cells thus become 
depolarized. During recovery, the ionic movement occurs in the opposite 
direction and the cell once again regains the negative resting membrane 
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potential. Local Anaesthetics block the sodium channel and thus prevent 
the depolarization in the neuronal membrane and  prevents conduction of 
impulses.  
PHARMACOKINETICS OF LOCAL ANAESTHETICS  
1. ABSORPTION  
Factors that affect the absorption of local Anaesthetic are:  
a. Site of Injection: Highly Vascular tissues show increase in the 
systemic absorption of local Anaesthetic and thus increase toxicity 
(I.V > tracheal > epidural  > sub-cutaneous).  
b. Presence of Vasoconstrictors: Vasoconstrictors decrease the 
systemic absorption and thus decrease the toxicity, this is only 
effective in short acting local anaesthetic, e.g.  Lignocaine.  
c. Type of local Anaesthetic: Local Anaesthetics with high tissue 
binding are more slowly absorbed. e.g.  Etidocaine.  
2. DISTRIBUTION  
Distribution of local Anaesthetics are affected by:  
a) Tissue perfusion: Highly perfused Organs (Brain, Liver) show 
higher uptake than poorly perfused organs (muscles and fat)  
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b) Plasma Protein Binding: the higher the protein binding the 
longer the time of retain of local anaesthetic in the blood.  
3. METABOLISM  
The Pharmacokinetic Property (Metabolism, Distribution and 
Excretion) of local Anaesthetics differ depending upon their chemical 
structure. Local anaesthetics with ester group are predominantly 
metabolized by pseudocholinesterase. Also one of the metabolites of ester 
local anaesthetics is P-Amino-Benzoic Acid (PABA) which is highly 
allergenic. In patients, who have genetically abnormal pseudo-
cholinesteras enzyme there is increased risk of toxic effects with this 
group of local anesthetic agents.  
Amide local anaesthetics are metabolized by microsomal enzymes 
in the liver. Metabolism will be impaired in patients with altered hepatic 
function or there is a decrease in hepatic blood flow thus leading to 
systemic toxicity. However allergic manifestations are less common with 
these  group of local anesthetics.  
4. PROTEIN BINDING  
Local Anaesthetics are bound to plasma proteins to varying 
degrees. It is assumed sometimes that drugs with the greatest degrees of 
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Lignocaine is a synthetic amino amide derivative of local 
anesthetics with intermediate potency and duration. It is the standard 
local anesthetics to which all other agents are compared. It is the most 
commonly used local anesthetic. It can also be used as an anti-
arrhythmic. It can be given by all routes. (intravenous, intrathecal, 
infiltration, local applications like ointment, sprays, jelly, etc. ) 
MECHANISM OF ACTION 
Lignocaine after entering the cell membrane binds to the inner 
portion of the resting sodium channel receptor. It prevents the 
propagation of nerve impulse through the ion-selective sodium channel in 
the nerve membranes. This decreases the depolarization rate, so that the 
threshold potential is not reached. Thereby, action potential generation is 
inhibited, without altering the membrane potential. 
PHYSIO-CHEMICAL PROPERTIES 
Molecular Weight  : 234 
Weak Base with a pKa :  7.6  7.8 
Stable, not decomposed by heating Acids or Alkalies compared to 
Bupivacaine,  it is less lipid soluble 
25 
 
PHARMACOKINETICS  
ABSORPTION 
Lignocaine is absorbed to systemic circulation from the site of 
application or injection. Blood-flow to that area and use of Epinephrine 
determines the rate or absorption. 
METABOLISM AND EXCRETION 
It is metabolized in liver by Oxidative de-Alkylation to  
mono-ethyl glycin exylidide which on further hydrolysis produces 
xylidide. Hepatic blood flow determines its metabolism. 80% activity of 
the parent drug is by mono ethyl glycine xylidide and 10% of its activity 
by Xylidide. 75% of Xylidide is excreted in the urine as 4–hydroxyl –  
2,6 – dimethylaniline. 
ONSET OF ACTION 
The onset of action varies with the site of application of 
Lignocaine. For topical Anaesthesia, its onset 5–10 minutes,  
For conduction anaesthesia, in small nerves, 5-10 minutes. For large 
nerves, 10–15 minutes. For intravenous administration 1–2 minutes.  
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70% of the drug binds to α1 Acid Glycoproteins. Volume of distribution 
91 liters.  
Lignocaine has a triphasic distribution.  
Rapid Distribution Phase (A) : During this phase, the drug is 
distributed to highly vascular regions with t ½ & of 1 minute. 
Slow Disappearance Phase (B) : Here the drug is distributed to 
slowly equilibrating tissues with t½ 1b pf 9.6 min. Finally the drug goes 
to slow transformation and Excretion phase (S) : 
Where the t½ is 1.6 hrs. 
Clearance – 0.95 litres per minute. 
AVAILABILITY 
• 2% lignocaine ointment, 5% lignocaine ointment 
• 10% lignocaine spray 
• 2% lignocaine Jelly 
• 4% lignocaine aqueous solution 
• 4% lignocaine viscous 
• 4% lignocaine with adrenaline as 1 in 200000 dilution – 30 ml vial. 
• 2% lignocaine with adrenaline as 1 in 200000 dilution 
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• 2% Lignocaine – plain – 30 ml vial – contains methyl and propyl 
paraben as preservative 
• 2% Lignocaine (Xylocard) without preservative – 50 ml vial for 
intravenoususe 
• 5% heavy 2 ml ampoules which contain 50 mg of lignocaine/ml 
with 75 mg  100 mg of dextrose 
PHARMACODYNAMICS 
LOCAL ACTIONS 
It acts locally causing loss of pain, touch and temperature 
sensation. Motor power and vasomotor tone is also lost in the region 
supplied by the nerves blocked. 
SYSTEMIC ACTIONS 
Its action depends on the site/route (intravenous) of administration. 
CARDIOVASCULAR SYSTEM 
It stabilizes the myocardial cell membrane. It depresses myocardial 
automaticity by inhibiting the action potential and reducing the duration 
of effective refractory period. At higher concentration, cardiac 
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conductivity and contractility are depressed. Lignocaine causes blockade 
of sodium channels in cardiac muscle leading to membrane changes and 
cardiac toxicity. It suppresses ectopic foci by stabilizing the membrane of 
damaged and excitable cells. 
VASCULAR SMOOTH MUSCLE 
It acts on vascular smooth muscle producing vasodilatation. 
RESPIRATORY SYSTEM 
Lignocaine depresses the ventilator response to low PaO2 (Hypoxic 
drive). Direct exposure of local anaesthetic to higher centres like medulla 
or peripheral nerves (intercostals, phrenic nerve) causes respiratory 
depression. Lignocaine has the property of relaxing bronchialsmooth 
muscles.Intravenous lignocaine is shown to be effective in reducing the 
reflex bronchoconstriction that can occur following airway manipulation. 
Central nervous System: Lignocaine causes a sequence of 
stimulation followed by depression. It causes sedation on intravenous 
administration. Sympathetic stimulation associated with airway 
manipulation leads to increased cerebral blood flow and increase in intra 
cranial pressure.  Intravenous administration of lignocaine is shown to 
blunt the sympathetic surge and attenuate these responses. Lignocaine 
29 
 
injection is capable of reducing the Minimal Alveolar Concentration of 
volatile Anaesthetics by 40%. 
Musculo-Skeletal : Lignocaine causes lytic degeneration, edema 
and necrosis of muscle fibres. 
Hematological : It enhances fibrinolysis thereby increasing the 
clotting time. 
INDICATIONS 
For infiltration block, peripheral nerve blocks, topical anaesthesia, 
intravenous regional anaesthesia, intra cuff injection (with sodium 
bicarbonate), spinal and epidural anaesthesia 
ANTI-ARRHYTHMIC 
Lignocaine is an antiarrhythmic drug because of cardiac membrane 
stabilizing properties. It is classified under class IB anti arrhythmic drug. 
It is used in the treatment of  
• Ventricular tachyarrhythmia 
• Arrhythmia due to acute myocardial Infarction during cardiac 
surgery 
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• Digitalis toxicity – since it does not worsen Atrio Ventricular – 
block 
1. It is used to prevent increases in intracranial pressure during 
intubation antitussive effect may be the reason for this action 
2. It suppresses noxious reflexes (coughing) & sympathetic 
stimulations associated with endotracheal suctioning and 
intubation. 
3. It is used intravenously as an analgesic for chronic pain states 
4. It is used as a supplement to general anaethesia 
CONTRA-INDICATIONS 
1. It should not be used in patients with (hypersensitivity) allergic 
disorder. 
2. It should not be used along with vasoconstrictor in digits of hand, 
feet and penis 
3. It is contraindicated in patients with stokes Adams syndrome, 
severe degree of heart block 
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DOSES : 
MAXIMUM RECOMMENDED DOSE : 
Plain `` - 3mg / kg 
Plain with adrenaline  - 7mg / kg 
Plain without preservative for reflex suppression – 1.5 mg / kg iv. 
DRUG INTERACTIONS 
B Blockers : Co-administration of beta blockers, increases the 
toxicity by increasing the serum levels of Lignocaine by reducing 
Lignocaine by reducing Lignocaine’s Metabolism. 
Anti-Convulsant Agents : It increase the metabolism of 
lignocaine 
Non-Depolarizing Muscle Relaxants : Lignocaine potentiates the 
blockade of non-depolarizing muscle relaxant. 
Opioids and a 2 Adrenergic Agonists : These drugs increases the 
analgesic action of Lignocaine. 
Anti-Arrhythmic Agents : Anti Arrhythmic Effect of Lignocaine 
is increased by these agents. 
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TOXICITY : 
Lignocaine Toxicity is due to systemic absorption of locally 
administered Lignocaine or due to accidental intravenous administration 
of large doses of Lignocaine. The central nervous system is most 
commonly affected. 
SYMPTOMS AND BLOOD LEVELS 
Light headedness, Tinnitus, Circumoral and Tongue Numbness 
(Anti-convulsant and Anti-arrhythmic activity)  :   4 micrograms / ml 
Visual disturbances  : 6 micrograms / ml 
Muscular twitching : 8 micrograms / ml 
Convulsions : 10 micrograms / ml 
Unconsciousness : 12 micrograms / ml 
Coma : 15 micrograms / ml 
Respiratory arrest : 20 micrograms / ml 
Cardiovascular collapse : 26 micrograms / ml 
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TREATMENT OF TOXICITY 
Lignocaine toxicity can be identified earlier by continuous 
monitoring of Cardiovascular and Respiratory status. 
• Barbiturates or Benzodiazepines are used to treat convulsion 
• Succinylcholine 1 mg/kg used to paralyze and to intubate the 
patient to have airway control during seizures. 
• Ventricular fibrillation can be treated by defibrillation. 
• 100% oxygenation, intubation and ventilation. 
• Maintain Blood Pressure by rapid infusion of Intra Venous fluids, 
use of vasopressors and put the patient in Trendelenberg’s 
position. 
• Treat electrolyte imbalance. 
ADVERSE EFFECTS 
1. Allergic and hypersensitivity reactions:  Methyl paraben used 
as a preservative causes allergic and hypersensitivity reactions. 
2. Cardio-vascular System : Hypotension, bradycardia. 
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MECHANISM OF ACTION OF  
LOCAL ANAESTHETICS 
The local anaesthetics inhibit the conduction of impulses across the 
nerves by the following mechanism as defined by Carvino. The local 
anaesthetic drug exists in both charged and uncharged forms. 
The Relative concentrations of the two forms are dependent on the 
pKa of the solutions, pH of the site where injected. The positively 
charged cation form is the active form. It produces local anaesthetic 
action. 
The uncharged base form is responsible for the diffusion across the 
liphophilic membranes across the cell. The drug acts from the inside of 
the cells on sodium ion channel. They occupy specific receptors on the 
inner side of sodium channel and inhibit the conduction of ions through 
them. Thus the cell remains in a state of persistent depolarization.  
This inhibits the propogation of action potential. 
Other probable site of actions are channel narrowing and 
membrane expansion due to nonspecific absorption across the cell 
membrane. Unchanged base form diffuses across hydrophobic pathways 
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of lipid membranes to reach specific receptor sites and protonation of 
drug to bind to inner opening of sodium channel. 
THE SURFACE CHARGE THEORY 
This theory is based on penetration of the axonal membrane by 
lipophilic portion of the local anaesthetic drug and neutralization of 
axolemmal negative charges on surface by the positively  charged 
terminal amino group of drug. The electro-negativity of the external 
membrane is counteracted by the acquired positive charges. This results 
in increase in the transmembrane potential without altering much of the 
intracellular resting potential. This inhibits the conduction of nerve 
impulses from the normal areas to anaesthetized areas of the nerve 
membrane. Thus it produces a conduction block across the two portions.  
According to surface charge theory the active form of local anaesthetic 
drug is the charged form of drug. 
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DEFINITION OF PAIN  
Pain is defined as “an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage.” This definition of pain 
considers the interplay between the objective, physiologic sensoryaspects 
of pain and its subjective, emotional and psychological components.  
Pain is clinically divided into, acute pain which is primarily due to 
nociception and chronic pain, which may also be due to nociception, but 
in which psychological and behavioral factors often play a major role. 
Postoperative pain is one of the types of acute pain and can be further 
differentiated based on the origin and feature into somatic and visceral 
pain. Somatic pain occurs due to abnormal nociceptive input from skin, 
subcutaneous tissues and mucous membranae.  
It is well-localized and usually described in terms of sharp, 
pricking, throbbing or burning sensation. Visceral pain on the other hand 
is due to nociceptive input arising from internal organ or one of its 
covering. It is usually dull diffuse pain. This visceral pain usually 
accompanied by abnormal parasympathetic and sympathetic 
manifestations like nausea, vomiting and sweating. It is also associated 
with changes in blood pressure and heart rate.  
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MAGNITUDE OF THE PROBLEM  
Occurrence, intensity, quality and duration of postoperative pain is 
influenced by multiple factors including the site, nature and duration of 
operation, type of incision (thoracic and upper abdominal operations are 
associated with the most severe pain), the preoperative psychological, 
physical and pharmacological preparation of the patient, added to this the 
anaesthetic management and the quality of post operative care  
(the attitude of the ward staff).  
NEURO-PHYSIOLOGY OF PAIN  
NOCICEPTORS  
Sensation is often described as either Protopathic (Noxious)  
or Epicritic (non-noxious). Epicritic sensation (light touch, pressure, 
proprioception, and temperature discrimination) is characterized by low-
threshold receptors (specialized endorgans on the afferent neurons) and 
conducted by large myelinated nerve fibers while; Protopathic Sensation 
(pain) is sub served by high-threshold receptors (free nerve endings).  
Noxious sensations have two components: a fast, sharp, and  
well-localized sensation “first pain” which is conducted by Aδ fibers;  
and a duller, slower onset, and poorly localized sensation “second pain” 
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which is conducted by C fibers. This protopathic pain is transmitted 
mainly by free nerve endings that sense mechanical or chemical tissue 
damage.  
Noxious sensations can often be broken down into two 
components: a fast, sharp, and well-localized sensation “first pain” which 
is conducted by Aδ fibers; and a duller, slower onset, and poorly 
localized sensation “second pain” which is conducted by C fibers. This 
protopathic pain is transmitted mainly by free nerve endings that sense 
mechanical or chemical tissue damage. 
SEVERAL TYPES OF THIS PAIN IS RECOGNIZED  
1. Mechano nociceptorsm : responds to sharp stimulus like 
pinprick,  
2. Silent nociceptors : responds only on the presence of 
inflammatiory mediators 
3. Polygonal mechano heat receptors : more common type of 
receptors, they respond to excessive pressure and extreme of 
temperature, they also respond to pain producing substances.  
Nociceptors are either somatic that include those in skin and deep 
tissues (muscle, tendons, joints), or visceral nociceptors that include those 
in internal organs.  
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PAIN PATHWAY  
Pain is conducted along three neuron pathways; from the periphery 
to the cerebral cortex.  
FIRST ORDER NEURON  
Neuronal cell bodies of the first order fibers are located in the 
dorsal root ganglia (for the body) and specific cranial nerve ganglia  
(for the head and neck) e.g. Gasserian ganglion for trigeminal nerve. The 
Proximal end of their axons reach spinal cord via the dorsal sensory root 
of cervical, thoracic, lumbar, and sacral level (for the body) and through 
the cranial nerves (for head and neck). 
40 
 
 
 
Figure – 2 
PAIN PATHWAY 
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SECOND ORDER NEURONS  
Pain fibers may ascend or descend in the spinal cord for 
approximately three segment levels in the Lissauer‟s tract and then they 
synapse with the second order neurons in the gray matter of the ipsilateral 
dorsal horn, this synapsing may be through interneurons. Second order 
neurons are either; nociceptive specific which serves only noxious stimuli 
and are normally silent or wide dynamic range (WDR) neurons that can 
receive also non-noxious afferent input. WDR neurons are more prevalent 
in the dorsal horn and are responsible for the increased intensity of firing 
in response to same stimulus “wind-up”.  
Lamina II of the gray matter of the dorsal horn of the spinal cord, 
(also called the substantiagelatenosa) contains many interneurons and is 
believed to play a role in the processing and modulating nociceptive 
input.  
Most of the Axons of second order neurons cross the midline to the 
contra-lateral aspect of the white matter of spinal cord forming the lateral 
spinothalamic tract that relays in the thalamus, synapses with the reticular 
formation fibers, synapses in raphynucleus. They also relay in 
periaquidactal gray matter 23,24.  
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THIRD ORDER NEURONS  
Thalamus is the relay center for second order neurons. The nerve 
cells of third order neurons are situated in the thalamus. These neurons 
send their axons to relay in the Somato-sensory area I and II of the 
Cerebral cortex 24,25,26.  
PREEMPTIVE ANALGESIA  
Preemptive Analgesia is defined as what is administered before 
surgical incision that prevent the development of central sensitization 
from incisional injury and inflammatory injuries (i.e., intra-operative and 
postoperative periods). Review of animal experiments, volunteer studies 
and clinical trials suggests that preemptive analgesia is a clinically useful 
and relevant phenomenon. Maximum benefit of preemptive analgesia 
protocol can occur only when there is near complete blockade of noxious 
stimuli is achieved.  
PAIN AFTER LAPAROSCOPY  
Studies have shown that pain after laparoscopy is less severe than 
same procedures done with conventional open procedures (Laparotomy). 
The reduction in pain has made the early discharge from the hospital 
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possible, provided that the control of the residual pain is adequate and 
that the drugs or techniques used for analgesia are safe.  
Various clinical reports have shown that pain after laproscopic 
cholecystectomy may be localized in the upper abdomen, lower abdomen, 
in the back, or to the shoulders. Upper abdomen pain more common in 
laproscopic surgery. It is shown that use of suxamethonium to facilitate 
tracheal intubation has no correlation with post laparotomy pain severity.  
Pain after laparoscopic procedures are usually transient, rarely it 
may persist for two to four days. After laparoscopic cholecystectomy, 
visceral pain was found to predominate in the first 24 hours, whereas 
shoulder pain was less severe in first post operative day and gradually 
increases and becomes significant on the successive days 28.  
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MECHANISM OF PAIN IN LAPAROSCOPY  
In addition to the trauma caused to the abdominal wall and the 
visceral organs by the endoscope and the surgical instruments, there are 
other mechanisms responsible for pain after laparoscopy. Rapid 
insufflation of Carbondioxide causes distension of the Peritoneum, 
trauma and tearing of small arteries and veins, traction of the nerve fibers 
and increase in release of inflammatory mediators and all these factors 
can contribute to development of post operative pain. Inflammation of the 
peritoneum is proposed to be the reason for origin of the upper abdominal 
pain after lower abdominal surgery or after diagnostic laparoscopy. 
Studies have shown that biopsy of peritoneum performed 2-3 days after 
laparoscopy showed inflammation and neuronal rupture. This pain may 
last for two to three days. 
Therefore, abdominal distention should better be slow with 
adequate muscle relaxation to ensure suitable abdominal compliance. 
Persistant gas in the abdomen may lead to excitation of Phrenic nerve 
presenting as persisting pain in the shoulder tip. Studies have shown 
strong correlation between gas bubble dimension and severity of pain 
score and it is also shown that aspiration of the gas under the diaphragm 
also decreases the pain score.  
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A: FACTORS INVOLVING WITH GASEOUS 
PNEUMOPERITONEUM  
1. Phrenic nerve injury (Neuropraxia) : It is due to distention of 
the diaphragm during gas insufflations.  The resultant phrenic 
nerve neuropraxia possibly contributes to the shoulder pain due to 
the C4 dermatome  involvement  (referred pain).  
2. The nature of insufflated gas and pH of Abdominal Cavity: 
CO2 in the abdominal cavity may dissolve and create an acidic 
environment. Studies have shown that intra-peritoneal pH was  
6.0 in the immediate post operative period and in the second post 
operative day it was recorded between 6.8–6.9 and then it 
gradually over a period of days normalizes to 7.030. The phrenic 
nerves may get irritated and damaged by the acidic environment 
and lead to the referred pain in the shoulder. The acidic 
environment can also trigger inflammation of the peritoneum and 
lead to persistant abdominal pain.  
3. Intra-abdominal Residual Gas: Several studies have shown 
correlation between residual intra-abdominal gas after 
laparoscopy and the severity of post-operative pain. Residual gas 
leads to prolonged intra-abdominal acidosis leading to prolonged 
peritoneal irritation thus increasing the morbidity. Residual gas is 
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also shown to alter the peritoneal surface tension leading to loss 
of support to the abdominal viscera. This lack of support leads to 
traction and visceral pain. 
4. Temperature of the insufflating Gas: Prospective randomized 
study conducted in laparoscopic gynaecological procedures 
comparing standard insufflation gas and gas insufflated in body 
temperature showed that pain intensity especially diaphragmatic 
and shoulder pain was significantly low in patients who were 
insufflated with warm gas and this low pain scores were observed 
for three days. 
5. Humidity of Gas: Humidity of gas reduces the post-operative 
pain laproscopic and abdominal surgery. It significantly reduces 
the post-operative ileus.  
B:OPERATIONAL FACTORS  
1. Wound Pain : Various type of abdominal incision done in 
laproscopic surgery. Sub costal incision causes nerve fibres 
damage. It leads to postoperative neuralgia.  
2. Abdominal Drainage : Abdominal drains are placed after 
laparoscopic surgery usually through one of the port site.  
It is done in the lateral abdominal wall and the incision traverses 
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multiple muscle layers. The umbilical port is usually avoided as it 
is related with greater incidence of pain, more risk of infection, 
and potential risk of incisional herniation if the defect is not 
closed in proper manner. Persistent drainage tube cause more 
inflammation leading to increase in post operative pain scores.  
Rather than routine procedure individualization for insertion for 
abdominal drain will help in reducing pain scores. 
C: PERSONALITY AND SOCIO-CULTURAL FACTORS  
Apart from surgical factors the personality of the patient and the 
socio-cultural factors can also influence the post-operative pain 
management, recovery of bowel movements and length of hospital stay. 
Previous pain experience, individual threshold for pain will also influence 
the individual postoperative pain perception and recovery time. 
Anesthesiologists have the responsibility of assessing the patients and 
providing adequate pain relief with appropriate technique on individual 
basis. 
Studies have shown that there is a substantial inter-individual 
variation in the occurrence, intensity and tolerance of pain after 
laparoscopic cholecystectomy. The intensity of pain after laparoscopic 
cholecystectomy peaks within the first 4-8 hours, has been reported to be 
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unbearable upto the first postoperative morning in one third of the 
patients. Pain after laparoscopic cholecystectomy involves three different 
components –  incisional pain – involving parietal component deep intra 
abdominal pain – visceral component shoulder tip pain – presumed 
referred pain from visceral component. These components differ with 
intensity of stimulation, duration of stimulus, and pathophysiological 
mechanisms. Studies have shown that in the immediate postoperative 
period the intensity of visceral pain dominates the other components. 
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EFFECTS OF POST-OPERATIVE PAIN  
Acute post-operative pain regardless of intensity and regardless of 
the site can affect all organ system, alter the homeostasis and strongly 
influences the postoperative morbidity and mortality.  
Consequences of acute post-operative pain is classically due to 
activation of sympathetic nervous system and the neuro endocrine stress 
response. Studies have shown that reduction in perioperative stress 
responses (Endocrine, Metabolic and Inflammatory) decreases the 
incidence of postoperative organ dysfunction, will lead to a reduced 
morbidity and mortality and thereby to an improved surgical outcome. 
(A) CARDIO-VASCULAR EFFECTS  
Cardiac disease is a major cause of perioperative death. The 
realization that, in high risk populations, perioperative myocardial 
ischemia is most likely to occur after surgery (from day one to day three 
postoperatively) has led to treatment strategies designed to prevent its 
development.  
Although a variety of factors may contribute to the development of 
postoperative myocardial ischemia, including hypothermia, anemia, 
anxiety, and tracheal intubation / suctioning, responses to poorly 
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controlled pain play a prominent role. In this regard, activation of 
sympathoadrenal, and neuroendocrine axes may have a major impact on 
myocardial oxygen supply and demand. Catecholamine-induced 
tachycardia, enhanced contractility, increased after load and increased 
preload from hypervolemia caused by enhanced release of arginine 
vasopressin and aldosterone, are well characterized determinants of 
increased oxygen demand. Increased oxygen demand, with hypervolemia, 
may precipitate ischemia and acute cardiac failure, especially in patients 
with poorly compensated coronary artery or valvular heart disease.  
Myocardial oxygen supply may be diminished as a result of 
pulmonary dysfunction, in particular, atelectasis secondary to pain-
induced hypoventilation and pulmonary edema resulting from stress-
induced hypervolemia. Other causes of reduced oxygen supply include 
coronary artery constriction secondary to high circulatory levels of 
catecholamine and increased coronary sympathetic tone, stress-induced 
increase in plasma viscosity and platelet-induced occlusion; and serotonin 
induced coronary vasospasm secondary to platelet aggregation.  
(B) PULMONARY EFFECTS  
Pulmonary function may be dramatically altered by surgically 
induced pain. The classical pulmonary response to upper abdominal 
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surgery, include an increase in respiratory rate with decreased tidal 
volume, vital capacity, forced expiratory volume and functional residual 
capacity. Those pathophysiologic alterations are characteristic of acute 
restrictive pulmonary disease and, as such, may be associated with 
clinically significant hypoxia and hypercarbia.  
Pain, due to activation of sympathetic nervous system causes 
increase in total body oxygen consumption and carbon-di-oxide 
production. This effect mandates that work of breathing has to be 
increased. Patients who undergo upper abdominal and thoracic surgical 
procedures are in high risk of inadequate ventilation, especially when 
post operative pain is not adequately controlled. Reduced depth of 
breathing and inadequate cough leads to further reduction in the tidal 
volume and functional residual capacity which in turn can cause 
atelectasis, intrapulmonary shunting and hypoxemia. This leads to further 
increase in post operative morbidity and mortality. 
 (C) GASTROINTESINAL EFFECTS  
Sympathetic hyperactivity induced by pain increases sphincter tone 
and decrease motility of intestine, causing ileus, pain also increases stress 
ulceration due to increase in gastric acid secretion.  
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(D) ENDOCRINAL EFFECTS  
The dominant neuro endocrine responses to pain involve 
hypothalamic – pituitary - adrenocortical interactions. Those interactions 
result in increased catecholamine and catabolic hormone release. This 
effects causes sodium and water retention, and increased levels of blood 
glucose, free fatty acids and lactate. Sympathetic activation also causes 
negative nitrogen balance and protein breakdown (catabolism) further 
impeding post operative outcome. 
(E) HEMATOLOGICAL EFFECTS  
The neuroendocrine stress response causes decrease in the levels of 
natural anticoagulants, inhibition of fibrinolysis and increase in platelet 
reactivity which initiate a postoperative hypercoagulable state. This 
hypercoagulability causes a series of other events such as deep venous 
thrombosis and myocardial ischemia.  
(F) IMMUNOLOGICAL EFFECTS  
The stress response potentiate postoperative immune suppression; 
the extent of which correlates with the extent of surgery. Stress response 
has been reported to depress the reticulo-endothelial system which 
predispose to infection.  
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G) PSYCHOGENIC EFFECTS  
Intense anxiety, fear, and the loss of control that accompany severe 
tissue injury may have profound impact on the hypothalamic-pituitary 
axis. Behavioral responses associated with poorly controlled pain include 
sleep deprivation and reduced morale.  
In many patients, uncontrolled postoperative pain can produce a 
series of long-term emotional disturbances, which could impair the 
patients’ health, and cause undue fear and anxiety if subsequent surgery is 
required. Studies have shown that up to 20% of major non-cardiac 
surgical patients experience post-operative cognitive dysfunction.  
This cognitive dysfunction may persist for 3 months after surgery in 
approximately 10% of the patients. 
(H) DEVELOPMENT OF CHRONIC PAIN  
Following major surgery neuropathic pain can develop due to the 
nerve fibers damage. Neuropathic pain diagnosed by burning sensation 
stinging or shooting pain and lack of response to doses of  Opioid. 
Lastly, optimizing treatment of acute postoperative pain can 
improve health-related quality of life, while poor postoperative pain 
control may intervene with patients day to day activities.  
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MEASUREMENT OF PAIN  
Pain Measurement can be done by Two methods:  
1. Type I Method 
2. Type II Method 
1. TYPE I METHOD  
Those are objective methods, done by the physician as he assigns 
numbers about the patient condition. It includes the following:  
Physiological Indices 
• Endocrinal (increase in serum cortisol and catecholamine). 
• Cardiovascular (increase in blood pressure and heart rate)  
• Respiratory (increase in respiratory rate and decrease  
in tidal volume)  
Neuro-Pharmacological   
• Correlation with Beta Endorphin  
(decreased in acute painful conditions)  
• Thermography (Hypo-emission in Chronic pain)  
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Neuological   
• Nerve conduction Velocity  
• Evoked Potentials  
• Single Positron Emission Tomography (SPET). 
Behavioural  
Sighing,  Crying, Shouting, Trembling. 
(2) TYPE II METHODS 
It includes either 
Single Dimension Methods   
• Category Scale (Verbal Rating Scale)  
• Numerical Rating Scale  
• Graphic Rating Scale  
Multi-Dimensional Methods 
• McGill Pain Questionnaire, MPQ  
• Dartmouth Pain Questionnaire, DPQ  
• West Haven-Yale Pain Questionnaire, WHYPQ  
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Measurement of pain in clinical practice depends largely on verbal 
dialogue between the patient and the doctor or nurse. A rating scale is 
mandatory in research projects and ideally when clinical data are being 
collected.  
Although pain is a subjective experience, great attention has been 
paid to the quantification of this experience. As pain is subjective 
experience, everyone has different perceptions of that experience. 
Differences are found in how individuals quantify pain. For example, 
some individuals would never say that their pain was a (10) on a scale 
from (0) to (10). On the other hand, other individuals report their pain as 
a constant (10) despite looking calm and relaxed. Also, all numeric scales 
used to measure pain have floor and ceiling effects. If the patients 
describe their pain to be a (10), there is no way to report an increase in 
pain intensity. 
A number of individual differences between patients make 
comparisons of pain measurements more difficult. For example, the past 
experiences of the patients influence their present perception of pain. 
Also, demographic factors such as gender, age, and ethnic background 
influence the individuals perception of pain. Again, patients who are 
clinically depressed and anxious tend to report increased pain intensity.                 
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Of most of the methods of pain scoring VAS and VRS are the most 
commonly used in the Single Dimension Method. 
THE VISUAL ANALOGUE SCALE (VAS)  
The visual analogue scale uses a straight line with extremities of 
pain intensity on either end. This line has 10 divisions (1 cm per division) 
with one depicting “no pain” and the other end being excruciating 
unbearable pain. The line can be either vertical or horizontal.  
The patients are asked to mark on the line to qualify the intensity of 
pain that they are currently experiencing. From the end labeled as “no 
pain” the mark placed by the patient is measured and adjusted to the 
nearest division.  
To assist in describing the intensity of pain, words can be placed 
along the scale (e.g., mild, moderate, or severe). Such descriptors can 
help to orient the patient for the degree of pain; this particular variation of 
the VAS has been known as a graphic rating scale. Explanation to the 
patient is needed by the clinician when using the VAS. Occasionally, the 
patient may be confused about the line, perceiving it to represent time of 
degree of relief rather than degree of pain intensity. 
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FIGURE: 3:  
VISUAL ANALOGUE SCALE 
 
THE VERBAL RATING SCALE  
Verbal Rating Scales are another means of assessing the varieties 
and intensities of pain. A verbal rating scale uses a list of words from 
which patients choose descriptors of their pain. There are a number of 
different verbal rating scales including four-item scales, five-item scales, 
six-item scales, 12-item scales, from the least intense to the most intense. 
The Prince-Henry pain scale is the most popular scale; it is a 5- point 
scale, words are often ranked according to severity and numbered 
sequentially from the scale which quantifies induce pain from 0 to 4 as 
shown below :   
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No pain on coughing : 
1. Pain on Coughing, but not on deep breathing  
2. Pain on Deep breathing, but not at rest  
3. Mild Pain at rest  
4. Severe Pain at rest 
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MANAGEMENT OF POST-OPERATIVE PAIN 
PROPHYLACTIC MEASURES  
Postoperative pain can be prophylactically reduced by proper 
preoperative and postoperative surgical and psychological care. Although 
the widely accepted definition of pain emphasizes on the cognitive and 
emotional response to tissue damage, the role of psychological method in 
the management of acute post operative pain is limited. However studies 
have shown that Psychological support improves the recovery,  reduces 
the postoperative pain intensity  and reduces the psychological distress 
after any surgical intervention. 
Psycho-educational care is described as health-care information 
provided to patients and patient relatives regarding- 
1. Patient  preparation for surgery,  
2. Timing and conduct of surgical procedures,  
3. Function and roles of health-care providers,  
4. Self-care actions 
5. Pain and discomfort information’s 
6. Teaching skills like coughing, breathing and bed exercises, 
relaxation, hypnosis 
7. Psychosocial Support (identifying and alleviating concerns, 
reassurance, problems solving, and encouraging questions).  
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Apart from pharmacological management good surgical and 
nursing care also helps to decrease postoperative pain severity. Skillful 
and smooth surgical handling of tissues in operative site, carry out the 
operation with dispatch and planning alternative surgical techniques to 
minimize trauma. Proper post-operative care help to decrease the 
magnitude of postoperative pain which involves continuing psychological 
support, proper care of wounds, early ambulation, and of course good 
nursing care. 
ACTIVE MEASURES  
Post-operative pain can be partially or completely relieved by one 
of the following methods :  
i. Systemic Analgesics and adjuvant drugs.  
ii. Local infiltration and field block.  
iii. Regional analgesia using local anaesthetic agents.  
iv. Regional analgesia with epidural or intrathecal opioids.  
v. Regional analgesia with combined local anaesthetic agents  
and opioids  
vi. Electrical analgesia achieved with transcutaneous electrical 
stimulation or electroacupuncture.  
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I. SYSTEMIC ANALGESICS AND ADJUVANT DRUGS 
A. NARCOTICS 
Exogenously administered opioids mimick the actions of 
endogenous opioid peptides (Enkephalins, B-Endorphins and 
Dynorphins) and acts on the specific opioid receptors within the central 
nervous system and causes pain relief. Pharmacological studies led to the 
proposal of five classes of opioid receptors. Each receptor mediates a 
spectrum of pharmacologic effects.  
All opiod agents commonly used in clinical practice produce 
analgesia through similar molecular mechanism. They bind to G-Protein 
coupled Opioid receptors in the neuronal membrane, subsequently 
leading to inhibition of adenylatecyclase. This causes activation of 
inwardly rectifying K-channels, and inhibition of voltage-gated calcium 
channels thus reducing neuronal excitability and pain impulse 
transmission.  
Whatever the route of administration the cardinal rule is to give the 
patient sufficient amount of analgesic drug to provide effective sustained 
pain relief, with minimal side effects. Optimal doses of narcotics given to 
patients in pain depress the respiratory center slightly; they decrease the 
ventilation/perfusion abnormality and thus improve oxygenation of 
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arterial blood, equally important the fact that pain relief permits patients 
to breath more deeply and to cough somewhat better when they are 
instructed by nursing and surgical staff. 
Although opioids are potent analgesics for control of postoperative 
pain, concerns regarding their side effects like increase incidence of 
nausea and vomiting, pruritis, sedation, respiratory depression and 
potential of inhibiting gastro intestinal motility have limited their use 
during  and after laparoscopic procedures.  
ROUTES OF ADMINISTRATION 
There is a wide inter-subject and intra-subject variability in the 
relationships of opioid dose, serum level and pain relief in the 
management of postoperative pain. Studies have shown that 
intramuscularly administered narcotics resulted in a wider variability in 
serum drug concentration than other intravenously administered one.On 
the other hand , intravenous route provide good and rapid analgesia but 
produce marked respiratory depression and thus the patient must be 
observed for 15-20 minutes after first injection to assess pain relief and 
undesirable side effects.  
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INTRAVENOUS PATIENT CONTROLLED ANALGESIA  
A significant improvement in postoperative analgesia was the 
development of appropriate delivery system that allows the use of 
intravenous patient–controlled analgesia (IVPCA). Pumps used allow the 
patient of inject a small bolus of an intravenous opioid drug whenever he 
or she feels pain, thus maintaining the analgesic book level in the 
appropriate range, pumps also has got a “lock-out” system which 
provides an adequate time delay for the patient to achieve analgesia from 
each injected dose, and also guards against over dosage that can lead to 
respiratory depression. Recent machines also provide a continuous 
infusion of analgesic which give the patient uninterrupted sleep but can 
lead to an increase in the total quantity of analgesic given. Morphine is 
the least expensive and perhaps the most popular, but the development of 
side effects (pruritis, nausea, dysphoria) may require switching to an 
alternative.  
Opioid can be given orally. Sustained release preparations are 
commercially available. They usually provides quick and effective 
analgesia and they can also be used to bridge the analgesic gap when 
there is plan to switch over from patient controlled anesthesia protocol to 
simple fixed analgesic regimen.  
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Transdermal opioids (Fentanyl patches) provide excellent 
alternative, especially when oral route is not allowed. Main advantage of 
transdermal route is that this technique bypasses the hepatic first-pass 
metabolism and effective pain relief is achieved for 2-3 days.However the 
onset of action is slow and unpredictable and option of altering the 
delivered dose depending upon the analgesic requirement is also not 
available thus limiting it’s use. 
PERIPHERAL OPIOID ANALGESIA  
Opioid related side effects are mainly related to the receptors 
present in the central nervous system. Many recent researches have 
shown that, apart from central nervous system and spinal cord, opioid 
receptors are also found in peripheral sensory nerves. These receptors are 
involved in pain modulations which are stimulated by endogenous opioid 
agonist production by inflammatory leukocytes. Inflammatory cells play 
a major role in peripheral opioid analgesia by migrating to and delivering 
opioid peptides to the receptors expressed by the sensory nerve terminal 
at the very site of tissue damage. Now many research are focused on 
developing a novel opioid agonist targeting these peripheral opioid 
receptors.  
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During surgery the tissue damage leads to inflammation. These 
inflammations cause leaky capillaries and extravasation of inflammatory 
cells. Corticotrophin releasing hormone, interleukin-1B and 
catecholamines play a major role in opioid release from the inflamed 
tissues. This leads to effective afferent blockade of pain signals and thus 
reducing the pain perception and sympathetic response to the perceived 
pain. As this mechanism involves inflammatory cells the action of 
peripherally applied opioids is apparent only in the presence of ongoing 
inflammation. Studies have shown that small dose of morphine applied to 
the injured site i.e incision site, produced significant analgesia with 
minimal side effects.   
 
PHARMACOLOGICAL PROPERTIES OF NARCOTICS  
CNS EFFECTS : Opioids eliminates pain, depresses respiration, 
suppresses cough, stimulates the third nerve nucleus causing miosis and 
stimulates the chemoreceptor trigger zone causing nausea and  
vomiting.  
HAEMODYNAMIC EFFECTS : Opioids cause Bradycardia and 
decrease the sympathetic tone.  
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SMOOTH MUSCLE EFFECTS : Opioids stimulate circular 
smooth muscles causing Biliary colic, retention of urine and bronchial 
constriction which is also partly due to histamine release.  
TOLERANCE : Some patients may develop tolerance to 
particular opiods over a period of time. When this occurs those patients 
also show tolerance to other opiods also. In this scenario non-opioid 
analgesics like NSAIDs can be useful for pain control. 
 
B. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS  
Non-steroidal anti-inflamatory drugs (NSAID) block the synthesis 
of prostaglandins by inhibition of the enzyme cyclo-oxygenase. Cyclo-
oxygenase enzyme catalyzes the conversion of arachidonic acid to the 
cyclic endoperoxide, which are the precursors of prostaglandins. As 
Prostaglandins are mediators of several components of the inflammatory 
responses like fever, pain and vasodilatation blocking their production 
will help in control of post operative pain caused by tissue injury and 
inflammation. Various NSAIDs are availablewith difference in potency 
with respect to their analgesic, anti-inflammatory and antipyretic 
properties.  
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Non-Steroidal Anti-Inflammatory Drugs are commonly used for 
pain relief in minor surgical procedures. They are also used as bridging 
drugs in patients who underwent major surgical procedures when they are 
transferred from opioid based drugs to less potent analgesics over a 
period of two to three days. NSAIDs have also been used early in the 
setting of major surgery in combination with opioids. Studies have shown 
that the quality of pain relief from these combination therapy is better 
than achieved than opioid alone therapy. Moreover, it has consistently 
been shown that NSAIDs given soon after major surgery reduce opioid 
requirements by about onethird.  
The three major problems associated with NSAID therapy are  
1. Gastropathy,  
2. Impaired hemostasis, and  
3. Nephrotoxicity.  
All are directly related to inhibition of prostaglandin synthesis. 
NSAIDs can also have idiosyncratic side effects that are not 
prostaglandin-mediated. Such idiosyncratic reactions are rare but can be 
serious. These may include exacerbation of bronchospasm, bone marrow 
toxicity, dermatological reactions, hepatitis and CNS symptoms.  
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C. PARENTRAL PARACETAMOL  
Paracetamol is a one of the non-opioid analgesics commonly used 
worldwide. It is considered to be the safest and cost-effective non-opioid 
pain killer when it is administered in analgesic dosages. Studies have 
shown that both parenteral and rectal paracetomol produces effective pain 
relief in the postoperative period. Studies have also shown that combined 
use of paracetamol with a Non-Steroidal Anti-Inflammatory Drugs is 
superior to paracetomol alone. Although the mechanism of action of 
paracetamol is not well defined there are increasing evidence of a central 
antinociceptive effect involving inhibition of COX-2 in central nervous 
system, inhibition of a putative central cyclooxygenase COX-3and 
modulation of inhibitory descending serotinergic pathways. Paracetamol 
inhibits prostaglandin secretion at the cellular transcriptional level, 
independent of cyclooxygenase activity. Although less potent than 
standard dose of opioids or the Non-Steroidal Anti-Inflammatory 
DrugsParacetamolis an effective postoperative analgesic as it has both 
central and peripheral mechanism of action for control of pain. Currently 
intravenous compatible preparations are also commercially available and 
studies have shown that analgesic and anti-inflammatory properties are 
better than oral and suppository preparations.  
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D. N-METHYL D–ASPARTATE ANTAGONISTS  
Ketamine is an NMDA antagonist and widely used in anesthesia 
management as anesthetic and analgesic agent. Apart from general 
anesthesia Ketamine is also used as an adjuvant analgesic agent in 
regional anesthesia procedures. Studies have shown that use of Ketamine 
(0.1–0.2 mgkg-1 IV) as an adjunctive to opioids resulted in excellent 
analgesia, less opioid related side effects, reduced opioid use and greater 
physician and patient satisfaction. Several studies have described the use 
of small-dose Ketamine in combined  with local anaesthetics or opioid 
analgesics in management of post operative pain in minor surgical and 
orthopedic procedures.  
Dextromethorphanis another NMDA receptor antagonist 
commonly used for pain management. One mechanism of pain 
transmission is wind up phenomenon occurring in dorsal colums of spinal 
cord mediated by NMDA receptors. As Dextromethorphan blocks 
NMDA receptors this drug reduces NMDA mediated nociceptive 
responses in dorsal horn neurons and thus enhance opioid, local 
anaesthetic and Non-Steroidal Anti-Inflammatory Drugs induced 
analgesia. Studies have shown that in patients undergoing laparoscopic 
cholecystectomy and inguinal herniorrhaphy procedures, 90 mg of 
dextromethorphan given through oral route provided good pain relief, 
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reduced opioid use, less sedation, less opioid related side effects and 
caused increased overall well being. 
E. ALPHA-2 ADRENERGIC AGONISTS  
Clonidine is a centrally acting Alpha Adrenergic Agonist.  It is 
used as oral formulation and also as intravenous formulation for peri 
operative pain mangement. It is also used as a part of multimodal 
analgesic regimen along with NSAIDs and opioids. Studies have shown 
that intravenous Infusion of clonidine in patients undergoing local or 
regional anesthesia management resulted in stable intraoperative 
hemodynamics and good post operative pain control.  
Dexmedetomidine is a newly introduced selectivealpa 2-agonist.  
It acts through spinal and supra spinal mechanism and causes reduction in 
noradrenaline output in pain transmitting fibers. Multiple studies in 
various type of surgical procedures have shown that use of 
Dexmedetomidine reduces postoperative pain, maintains sedation and 
decreases opioid analgesic use and related side effects. 
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F. MISCELLANEOUS NON-OPIOID COMPOUNDS  
Gabapentin initially introduced as an anticonvulsant, now it is 
being used in acute post operative pain management and also in chronic 
pain management. Studies have shown that oral administration of 
Gabapentin (1.2g) as a premedication significantly reduced post-operative 
pain scores and supplemental analgesic use without increasing adverse 
effects.  
Magnesium, is a divalent cation, and through blocking the calcium 
mediated pain transmission in spinal cord it provides anti-nociceptive 
effects. Studies have shown that magnesium 50 mg/kg given 
intravenously as a bolus dose at induction of anaesthesia resulted in lower 
pain scores, less opioid requirements and better patient satisfaction in 
orthopedic procedures. Studies have also shown that magnesium when 
used intrathecally, It prolongs the fentanyl mediated analgesia.  
Neostigmine is a cholinesterase inhibitor that causes increase in 
acetylcholine levels in the spinal cord. This blocks the ascending pain 
impulse transmission and also descending pain response thus resulting in 
pain control. Studies have shown that when used in the dose of  
10–200μg in the subarachnoid or epidural spaces better reduction in pain 
scores are observed. As the mechanism of action is localized to spinal 
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cord neuraxial administration of neostigmine has been reported to possess 
better analgesic properties than systemic administration. In patients who 
underwent knee surgeries epidurally administered neostigmine (1μg/kg) 
produced more than 5 h of pain relief. Although neuraxial neostigmine 
acts as good pain killer, 15-30% of patients experience nausea and 
vomiting. Sedation is also common side effect of neostigmine.  
Inositol Triphosphate is a  new anti-inflammatory drug, shown to 
have properties of reducing postoperative pain and reducing the need for 
opioid analgesics after cholecystectomy.  
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II. LOCAL INFILTRATION  
AND FIELD BLOCK 
Infiltration of the wounds with dilute solution of Bupivacaine  
or use of rectus block for abdominal incision has been found effective in 
partially relieving postoperative pain after laparoscopy. Studies have 
shown that local anesthesia infiltration before incision offers an 
advantage of intra-operative pain relief and also supplements post 
operative analgesia than infiltration after the closure of incision.  
REGIONAL ANALGESIA WITH LOCAL ANAESTHETICS  
Epidural anaesthesia may be performed at any one of the four 
segments of the spine (cervical, thoracic, lumbar, and sacral). Sacral 
epidural anaesthesia is usually referred to as caudal anaesthesia. Thoracic 
epidural analgesia is technically more difficult and the possibility of 
injury to the spinal cord is greater.  
CONTINUOUS SEGMENTAL EPIDURAL BLOCK  
Continuous epidural analgesia is also an attractive option for  
post-operative pain management. Drug infusion can be intermittent bolus, 
continuous infusion with commercially available epidural infusion pumps 
and with patient controlled analgesia regimen. In the technique of patient-
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controlled epidural analgesia with a bolus dose adequate pain control is 
achieved. Then the analgesia is maintained with continuous low dose 
infusion. And when the patient feels pain bolus drugs will be given by 
demand injections which are operated by patients but the bolus dose and 
lock out period controlled by the physician. This technique has the 
advantage of minimizing drug dosage, flexibility of dosing, better patient 
satisfaction and reduced demand on physician time. The used pump must 
be able to give a continuous set infusion rate, to give demand doses with 
set lockout periods, and to limit a total dose over a set period of time. 
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REVIEW OF LITERATURE 
In a study titled “Perioperative intravenous lidocaine infusion on 
postoperative pain relief in patients undergoing upper abdominal surgery” 
The study was done to assess the efficacy of intravenous lidocaine 
infusion started perioperatively on postoperative pain intensity and 
analgesic requirement. Sixty patients undergoing major upper abdominal 
surgery were recruited it was a randomized double blinded study done in 
patients undergoing upper abdominal surgeries (n=60).  
They were divided into two groups, each contains 30 patients. One 
group received 2% lidocaine (intravenous bolus 1.5 mg/kg followed by 
an infusion of 1.5 mg/kg/h),and other group received normal saline. 
Before 30 minutes of skin incision the infusion was started and it was 
stopped one hour after the end of surgery. The intensity of pain and 
requirement of analgesia (Diclofenac) were assessed postoperatively for 
one hour at the interval of 15 minutes then 4th hourly up to 24 hours.  
The intensity of pain at rest and movement as well as the total 
postoperative analgesic requirement were significantly lower  
(142.50 ± 37.80 mg vs.185.00 ± 41.31 mg, P < 0.001) in Lidocaine group. 
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The extubation time was significantly longer in Lidocaine group 
(14.43 ± 3.50 minutes vs. 6.73 ± 1.76 minutes, P < 0.001). The time for 
the first dose of analgesic requirement was longer in Lidocaine group 
(60.97 ± 18.05 minutes vs. 15.73 ± 7.46 minutes, P < 0.001).  
It was concluded that perioperative infusion of low dose of Lidocaine 
decreases postoperative pain intensity, reduces the post-operative 
requirement of analgesia, without causing much side effects in patients 
undergoing  elective upper abdominal surgeries. 
A study titled “The effects of intravenous Lidocaine infusion on 
hospital stay after major abdominal pediatric surgery”. It was a 
randomized double blinded study which contains eighty pediatric patients 
aged 1–6 years, ASA II, III posted for abdominal major surgery were 
randomly divided into two groups, each of forty children. Children in 
control group received normal saline in a rate of 1.5 ml/kg/h and those in 
Lignocaine group received Lignocaine 1.5 mg/kg intravenously twenty 
minutes before induction, then received the infusion of 1.5 mg/kg/hr  
post-operatively upto 6 hours. They reported the length of hospital-stay 
and return of bowel function. Plasma Cortisol was recorded at baseline, 
10 minutes after continuous infusion, 5 minutes after intubation and 
10 minutes after extubation.  
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Serum lignocaine concentrations were recorded 10 minutes after 
start of infusion, 10 minutes and 4 hours after extubation. Patients in 
placebo group showed significant higher plasma cortisol concentrations 
(P = 0.001) in response to induction of anesthesia and extended 
postoperatively when compared to Lignocaine group. 
A Study titled “Perioperative intravenous Lidocaine has preventive 
effects on postoperative pain and morphine consumption after major 
abdominal surgery. A randomized prospective study conducted  
40 patients undergoing major abdominal surgery participated. Out of  
20 patients received intra venous 2% Lidocaine (bolus injection of  
1.5 mg/kg in 10 min followed by an IV infusion of 1.5 mg. kg(-1). h(-1)), 
and twenty patients received saline placebo.  
The starting time of infusion 30 min before skin incision and was 
stopped 1 hour at the end of procedure. Ligocaine blood-level measured. 
Post-operative pain scale (numeric rating scale of 0-10) and morphine 
consumption (patient-controlled analgesia) were assessed up to 72 hr 
after surgery. Mean Lidocaine levels during surgery were 1.9 ± 0.7 
microg/mL. Patient-controlled analgesia with morphine produced good 
post-operative analgesia (numeric rating scale at rest, < or = 3;  
90% - 95%; no group differences).  
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Patients who received intra venous Ligocaine group less pain 
during movement and needed less morphine usage during the first 72 hr 
after surgery (103.1 ± 72.0 mg vs. 159.0 ± 73.3 mg; Student's t-test;  
P < 0.05). Because this opioid - sparing effect is most pronounced on the 
3rd post-operative day, IV intra venous Lidocaine may have a true 
preventive analgesic activity, most likely by preventing the induction of 
central hyperalgesia in a clinically relevant manner. 
A study titled “Effect of Intra-operative Intravenous Lidocaine on 
Post-operative Pain and Return of Bowel Function After Laparoscopic 
Abdominal Gynecologic Procedures” A total of fifty patients were 
included, and five patients were withdrawn from the study, leaving forty 
five patients  (Control group, 21; experimental group, 24) for final 
analysis. Decreased overall analgesic requirements were noted in the 
experimental group compared with the control group but failed to achieve 
statistical significance at any time interval. Pain scores were similar 
between the groups except on third postoperative measurements, when 
the overall Visual Analogue Scale score was 3.5 ± 3.1 in the control 
group compared with 1.6 ± 2.4 in the experimental group (P = .02).  
A study titled “Intravenous Lidocaine infusion facilitates acute 
rehabilitation after Laparoscopic Colectomy”. A Randomized prospective 
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study 40 patients scheduled to undergo laparoscopic colectomy were 
randomly divided into two groups. Group 1 receive intravenous lidocaine 
(bolus injection of 1.5 mg/kg Lidocaine at induction of anesthesia, then a 
continuous infusion of 2 mg.kg.h intra-operatively and 1.33 mg.kg.h for 
24 h post-operatively) or an equal volume of saline.  
All patients received similar intensive post-operative rehabilitation. 
Postoperative pain scores, opioid requirement, and fatigue scores were 
measured. Passing of first flatus, defecation, and hospital discharge were 
recorded. Postoperative endocrine (cortisol and catecholamines) and 
metabolic (leukocytes, C-reactive protein, and glucose) responses were 
measured for 48 hours. Data (presented as median [25-75% interquartile 
range], lidocaine vs. saline groups) were analyzed using Mann-Whitney 
tests. P < 0.05 was considered statistically significant.  
A study titled “intravenous Lidocaine speeds the return of bowel 
function, decreases postoperative pain, and shortens hospital stay in 
patients undergoing radical Retropubic Prostatectomy”. A randomized 
study 40 patients undergoing radical retropubic prostatectomy were 
studied with one half of the patients receiving a Lidocaine bolus  
(1.5 mg/kg) and infusion (3mg/min, unless weight < 70 kg, then  
2 mg/min); the other half received a saline infusion. A blind observer 
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noted the patient's daily pain score, the time the patient first experienced 
flatulence and had the first bowel movement, and the total use of 
analgesics. Lidocaine group patient have experienced first flatulence in a 
significantly shorter time (P < 0.01) than control patients. Lidocaine 
patients' hospital stay was also significantly shorter (P < 0.05); on 
average, they spent 1.1 fewer days in the hospital. I.V.  Lidocaine 
initiated before anesthesia and continued 1 h postoperatively significantly 
sped up the return of bowel function. Lidocaine patients were also more 
comfortable postoperatively. Most of the bowel function benefits 
attributed to epidural Lidocaine are also present when the drug is 
administered parenterally. The length of hospital stay also reduced in 
Lidocaine-group. 
A study titled “Intravenous lignocaine infusion forneuropathic pain 
in cancer patients– a preliminary study” The effectiveness and duration of 
pain relief with a intravenous Lignocaine infusion was observed in ten 
cancer patients.  
All the ten patients were suffering from pain of neuropathic origin, 
having two or more of the symptoms: burning, aching, all odynia, 
reduced sensitivity to touch or pain, hyperaesthesia, nightly exacerbation 
and sleep disturbance. The patients received intravenous Lignocaine in a 
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dose of 5 mgkg-1 in 1ml.kg-1 of normal saline over 1 hour. Significant 
pain relief  (‘t’ value > ‘t’ at 0.01), dysaesthetic sensations, paraesthesias 
and nightly exacerbations were seen in the majority of patients upto  
14 days. Statistical analysis were performed using the unpaired ‘t’ test 
and analysis of variance (through application of  X2 test).  
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METHODOLOGY 
After obtaining necessary approval from Institutional ethical 
committee, this prospective randomized single blinded case control study 
was started.  
The study was conducted in Institute of Anesthesiology,  
Govt. Rajaji Hospital, Madurai.  
The study subjects were selected from patients posted for 
Laparoscopic Cholecystectomy. 
The inclusion criteria were : 
American Society of Anesthesiology (ASA) Grading 1 & 2 
Age  >  18 years 
Both Gender 
The exclusion criteria were : 
ASA 3, 4 
H/o Allergy to Lidocaine 
 H/o Anti-arrhythmic Drugs 
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 H/o Drug abuse 
 H/o Chornic Alcoholism 
 H/o Cardiac Diseases 
 H/o Bleeding Disorder 
H/o Liver Disease 
Patient Refusal 
After assessing Inclusion & Exclusion criteria 60 patients were 
selected. Informed consent was obtained from patients who were willing 
to participate in the study.  
On the day of surgery, patients were shifted to operating room. 
Intravenous access was obtained with 18 gauge Cannula. Electro-
cardiogram (ECG), Non-Invasive Blood Pressure (NIBP) and Pulse 
Oximeter were attached and baseline heart rate, saturation of  
Hemoglobin (SpO2) and blood pressure were recorded.  
  
85 
 
The patients were randomized into two groups by closed card 
method as follows : 
i.) GROUP I : Patient receive Inj. 2% Lidocaine 1.5mg /Kg IV 
bolus before induction & intravenous infusion dose of Inj. 2% 
Lidocaine (1.5mg/Kg) started before skin incision and 
continued for one hour. 
ii.) GROUP II : Patient receive 100ml Normal Saline started 
before skin incision. 
Patient were induced with Inj. Fentanyl 2mcs/Kg, Inj. Thiopentone 
Sodium 5mg/Kg and Inj. Succinyl Choline 2mg/Kg; intubated; controlled 
ventilation started with  N2O : O2  3:2 
Patients were monitored intra-operatively with ECG, NIBP and 
SpO2. 
After completion of surgery, the patients were given Inj. 
Neostigmine and Inj. Glycopyrrolate. After demonstration of recovery, 
from muscle relaxants patients were extubated and shifted to  
Post-operative Care Ward.  
Post-operative pain-score assessed with VISUAL ANALOGUE 
SCALE (over 10 points) immediately after extubation and upto 6 hours. 
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Patients demanding Analgesia or pain score more than 4/10 were given 
rescue analgesia with Inj. Pentazocine Lactate 15mg through intravenous 
route. Bowel sounds were assessed every hour and first observed time 
was noted. 
IN OUR STUDY, THE FOLLOWING PARAMETERS  
WERE OBSERVED : 
DEMOGRAPHIC FACTORS  
Age (Years) 
Gender (Male / Female) 
Weight (Kilograms) 
Surgery Duration (Minutes) 
INTRA OP HEMODYNAMICS  
(Assessed in Baseline, 10, 20, 30, 40, 50, 60 min. and  
post extubation) 
Heart Rate (Per Minute) 
Mean Blood Pressure (mmHg) 
SpO2 (%) 
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POST OP ASSESSMENT 
Visual Analogue Scale (Post extubation, 30 min, 1, 2, 4 and  
6th hour) 
Episodes of Rescue Analgesic Use 
Dose of rescue analgesic used 
Return of bowel sound 
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STATISTICS 
NULL HYPOTHESIS 
Lidocaine  infusion started before induction and continued for one 
hour intra-operatively will result in no significant difference in intra-op 
haemodynamics, recovery characteristics, post operative pain and early 
return of bowel function compared to placebo. 
STATISTICAL ANALYSIS 
SPSS version 16 (SPSS inc, Chicago 2007) was used for statistical 
analysis. 
Student ‘t’ Test used for comparison of Age, Weight, Duration of 
surgery, post-op pain scores, episodes of rescue analgesia use,  
dose of analgesics used and return of bowel sounds (Parametric data) 
Chi-Square Test used for comparison of Gender, ASA grading 
and number of patients received rescue analgesics (non-parametric data) 
One-way ANOVA used to assess the changes in hamodynamics 
during intra operative period. 
P <  0.05 considered statistically significant 
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CHART 6:  
COMPARISON OF INTRAOPERATIVE  
HEART RATE 
 
 
 
  
BASELIN
E
10 MIN 20 MIN 30 MIN 40 MIN 50 MIN 60 MIN
POST 
EXTUBA
TION
LIGNOCAINE 74.3 76.3 75.8 74.7 73.7 72.9 73.1 75.5
CONTROL 74.4 78.2 80 81.2 81.9 81.9 83.7 85.5
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CHART 7:  
COMPARISON OF INTRAOPERATIVE MEAN BLOOD 
PRESSURE  
 
 
  
BASELIN
E
10 MIN 20 MIN 30 MIN 40 MIN 50 MIN 60 MIN
POST 
EXTUBAT
ION
LIGNOCAINE 89.3 90.5 91 91.1 90.8 89.7 90.1 91
CONTROL 87.1 90.8 92.6 94 94.8 95.2 95.7 96.8
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CHART 8:  
COMPARISON OF INTRAOPERATIVE SPO2 
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The distribution of ASA Grading were comparable between two 
groups (p-0.781) (Table 1) (Chart 4) 
The duration of Surgery were comparable between two groups  
(p- 0.681) (Table 1) (Chart 5) 
On analyzing intra operative hemodynamics, heart rate in 
Lignocaine group showed no significant difference from baseline  
(p - 0.402). Similar to heart rate mean blood pressure was also showed no 
significant difference between baseline (p0.832). This analysis shows that 
Heart rate and blood pressure were maintained in Lignocaine group 
(Group I). (Table 2) (Chart 6,7) 
On analyzing heart rate and blood pressure changes in control 
group (Group II) there were statistically significant difference from 
baseline throughout the surgery (p < 0.001) indicating significant 
alteration in hamodynamics in control group. (Table 2) (Chart 6,7) 
Although SpO2 values in both groups showed statistically 
significant difference in both group all values were above 99%. (Table 2) 
(Chart 8) 
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TABLE 1 :  
Intra-operative Hemodynamics 
 
Base 
line 
10  
min 
20 
min 
30 
min 
40 
min 
50 
min 
60 
min 
Post  
extu-
batio
n 
p 
Lignoca
ine 
Heart  
Rate 
74.3  
±  
8.1 
76.3  
±  
7.0 
75.8 
± 
6.1 
74.7 
± 
6.7 
73.7 
± 
6.8 
72.9 
± 
6.6 
73.1 
± 
6.6 
75.5 
±  
6.2 
0.40
2 
Control 
Heart  
Rate 
74.4 
± 
7.2 
78.2  
± 
7.2 
80.0 
± 
6.4 
81.2 
± 
6.2 
81.9 
± 
6.2 
81.9 
± 
6.4 
83.7 
± 
6.6 
85.5  
±  
5.8 
0.00
0* 
Lignoca
ine 
mean  
BP 
89.3  
± 
5.7 
90.5 
± 
5.0 
91.0 
± 
4.3 
91.1 
± 
4.7 
90.8 
± 
5.0 
89.7 
± 
5.5 
90.1 
± 
5.7 
91.0 
± 
5.2 
0.83
2 
Control 
mean  
BP 
87.1 
± 
4.5 
90.8 
± 
4.2 
92.6 
± 
4.0 
94.0 
± 
5.0 
94.8 
± 
4.1 
95.2 
± 
4.0 
95.7 
± 
3.2 
96.8  
±  
4.2 
0.00
0* 
Lignoca
ine 
SpO2 
99.6 
± 
0.6 
99.8 
± 
0.4 
99.9 
± 
0.2 
100 
99.9 
± 
0.3 
99.9 
± 
0.1 
100 
99.8  
±  
0.3 
0.00
0* 
Control 
SpO2 
99.6 
± 
0.6 
99.7 
± 
0.3 
99.9 
± 
0.2 
99.9 
± 
0.1 
100 
99.9 
± 
0.2 
99.9 
± 
0.1 
99.8  
±  
0.4 
0.00
0* 
Data shown as Mean ± SD 
*Denotes Significant ‘p’  value 
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On analyzing the mean pain scores in both groups we found that in 
patients who received Lignocaine the mean pain scores were  
low compared to control group in all time points. (p< 0.001, p< 0.001,  
p< 0.001, p< 0.001, p- 0.001, p-0.008). (Table 3) (Chart 9) 
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TABLE 2 :  
Mean Pain Scores in Post-Operative period 
 
Group I  
(i.v Lignocaine) 
Group II  
(Control) 
p 
Post  
extubation 
0.53 ± 0.78 1.5 ± 1.0 0.000* 
30 min 0.6 ± 1.03 1.87 ± 1.4 0.000* 
1 hour 0.53 ± 0.68 2.43 ± 1.5 0.000* 
2 hours 0.83 ± 0.87 2.37 ± 1.4 0.000* 
4 hours 1.5 ± 1.5 2.8 ± 1.3 0.001* 
6 hours 1.87 ± 1.6 2.9 ± 1.3 0.008* 
Data shown as Mean ± SD 
*Denotes significant ‘p’ value 
Episodes of rescue analgesia use were also statistically lesser in 
lignocaine group (p < 0.001). Mean analgesic dose was also lesser in 
patients who received lignocaine (p < 0.001) (Table 4)(Chart 10).  
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Seven patients in group I received rescue analgesia compared to  
22 patients in group II and the difference was also statistically significant 
(p < 0.001) (Table 4)  (Chart 11) 
Mean time of onset of bowel movements was 23.5 hours in  
Group I and 33.1 hours in Group II and the difference was statistically 
significant (p-0.009) (chart 12) 
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TABLE3 :  
Rescue Analgesia and Return of Bowel Movements 
 Group I  ( i.v Lignocaine) 
Group II  
(Control) p 
Episodes of  
Rescue Analgesia Use 0.27 (0.521) 
1.17 
(0.913) 0.003* 
Dose of  
Pentazocine (mg) 4 (7.8) 17.5 (13.6) 0.003* 
Patins receiving 
Aescue Rnalgesia 
(Yes : No) 
8 : 22 23 : 7 0.000* 
Return of Bowel 
movements (hours) 23.5 (2.2) 33.1 (3.5) 0.009* 
Data shown as Mean (SD) 
* Denotes significant ‘p’ value 
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DISCUSSION 
In this study, 60 patients were enrolled, divided in to two groups, 
30 in each group. The result of this demonstrated that there was  
no statistically significant difference in age, sex, ASA grading, duration 
of the surgery and weight of the patients On analyzing intra operative 
hamodynamics, heart rate in Lignocaine group showed no significant 
difference from baseline (p-0.402).  
Similar to heart rate mean blood pressure  was also showed no 
significant difference between baseline (p0.832). This analysis shows that 
Heart rate and blood pressure were maintained in Lignocaine group 
(Group I). On analyzing heart rate and blood pressure changes in control 
group (GroupII) there were statistically significant difference from 
baseline throughout the surgery (p<0.001) indicating significant alteration 
in hamodynamics in control group. Although SpO2 values in both groups 
showed statistically significant difference in both group all values were 
above 99%. Post operatively pain score assessed by Visual analogue 
scale.  
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On analyzing the mean pain scores in both groups, we found that in 
patients who received Lignocaine the mean pain scores were low 
compared to control group in all time points. (p< 0.001, p< 0.001,  
p< 0.001, p< 0.001, p- 0.001, p-0.008). If the patient have VAS more than 
4 Pentazocine lactate 15mg. given.  
Episodes of rescue analgesia use were also statistically lesser in 
lignocaine group (p<0.001). Mean analgesic dose was also lesser in 
patients who received lignocaine (p < 0.001). Seven patients in  
Group I received rescue analgesia compared to 22 patients in group II and 
the difference was also statistically significant (p < 0.001).  
Bowel movements assessed. Mean time of onset of bowel movements 
was 23.5 hours in Group I and 33.1 hours in Group II and the difference 
was statistically significant (p-0.009).  
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SUMMARY  
In this study, we evaluate the impact of intravenous Lignocaine on 
Intraoperative haemodynamics, recovery characteristics, post of pain 
scores,post op analgesic requirement & Return of bowel function in 
patients undergoing laproscopic cholecystectomy. Sixty patients of  
ASA 1&2 of either sex divided into two groups, thirty patients in each 
group.  
Group L – Lidocaine Group 
Group S – Saline Group 
The study was done at Govt. Rajaji Hospital and Madurai Medical 
College between the period of 3 years.  
In our study, group the Age of the patients, Sex distribution and 
weight are not statistically significant. There is stable introperative 
hamodynamics, heart rate, mean blood pressure in lidocaine group. There 
is lower post operative pain score in lidocaine group. Early bowel 
movements  in lidocaine group. 
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CONCLUSION  
Lidocaine Infusion started (1.5mg/Kg) before induction and 
continued (1.5mg/Kg/Hr)  for one hour intra-operatively results in intra-
op hamodynamic stability, lesser post operative pain, lesser use of rescue 
analgesics and early return of bowel function compared to placebo.  
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PROFORMA 
Name : 
Age & Sex : 
Weight : 
        Date & Time of Admission:               Date & Time of Discharge: 
Diagnosis : 
Procedure : 
History : 
Clinical Examination : 
Basic Investigation : 
Anaesthetic Technique : 
Dosage of Drug : 
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Post-op. Pain score by VAS 
Complication, if any: 
Duration of surgery: 
Monitoring of  Vitals every 15 min 
 
VITALS 2  min. 
15 
min. 
30  
min. 
45 
min. 
1 
hr 
1 hr. 
15min. 
1 hr. 
30 
min. 
PULSE        
B.P        
RR PATERN        
SPO2        
ECG        
SIDE 
EFFECTS 
       
REMARKS        
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